Skip to Content

'
Tapan M. Kadia, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001 Robert Wood Johnson Medical School, Piscataway, NJ, MD, Doctor of Medicine
1998 Rutgers University, New Brunswick, NJ, BA, Bachelor of Arts

Postgraduate Training

7/2004-6/2005 Chief Residency, Baylor College of Medicine Affiliated Hospitals, Houston, TX
7/2002-6/2004 Clinical Residency, Baylor College of Medicine Affiliated Hospitals, Houston, TX
7/2001-6/2002 Clinical Internship, Baylor College of Medicine Affiliated Hospitals, Houston, TX

Board Certifications

8/2004 Internal Medicine, American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2008-9/2015

Institutional Committee Activities

Member, Credentials Committee, MD Anderson Cancer Center, 9/2013-present
Member, MD Anderson Hematology and Medical Oncology Board Review Steering Committee, 1/2012-present
Member, Clinical Affairs Subcommittee, Faculty Senate, MD Anderson Cancer Center, 9/2011-present
Member, Faculty Senate, 9/2011-present
Member, Clinical Research Committee, MD Anderson Cancer Center, 7/2010-present
Member, Leukemia Department Representative, Fellowship Steering Committee, 1/2010-present

Honors and Awards

2006 AACR/ASCO Workshop Methods in Clinical Cancer Research Vail
2006 AACR/ASCO Workshop Molecular Biology in Clinical Oncology Aspen
2006 FOREM Lymphoma Research Award, Runner up
2006 Recipient of The Paul Calabresi Clinical Oncology Award-K12 Grant
2004 Chief Residency, Internal Medicine, Baylor College of Medicine
2000 Articulated BA/MD Program
2000 Dean's List, Rutgers College
2000 Member, Golden Key National Honor Society
2000 Member, Phi Beta Kappa Honor Society
2000 Member, Phi Eta Sigma Honor Society
2000 Recipient of The Waksman Fellowship for Undergraduate Research
2000 UMDNJ Research Fellowship
1998 Norman Reitman Scholar
1996 Rutgers College Award of Excellence
1995 Rutgers College Award of Excellence

Professional Memberships

American Association of Cancer Research (AACR)
Member, 1/2013-present
American Society of Clinical Oncology (ASCO)
Member, 1/2000-present
American Society of Hematology (ASH)
Member, 1/2000-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol 90(9):769-73, 9/2015. e-Pub 7/2015. PMCID: PMC4546505.
2. Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA Oncol 1(6):820-8, 9/2015. PMID: 26181162.
3. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt , Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732-6, 8/2015. e-Pub 5/2015. PMID: 26016821.
4. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. e-Pub 8/2015. PMID: 26299958.
5. Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs 33(4):870-80, 8/2015. e-Pub 5/2015. PMID: 25933833.
6. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 8/2015. e-Pub 2/2015. PMID: 25716073.
7. Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-63, 8/2015. e-Pub 6/2015. PMID: 26088933.
8. Kadia TM, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H. Decitabine improves outcomes in older patients with acute myeloid leukemia (AML) and higher blast counts. Am J Hematol 90(7):E139-41, 7/2015. e-Pub 5/2015. PMCID: PMC4478207.
9. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer 121(14):2375-82, 7/2015. e-Pub 3/2015. PMID: 25809968.
10. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 7/2015. e-Pub 2/2015. PMCID: PMC4486227.
11. Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica 100(5):653-61, 5/2015. e-Pub 2/2015. PMCID: PMC4420214.
12. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma 56(4):1-8, 4/2015. e-Pub 8/2014. PMCID: PMC4326620.
13. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90(4):276-81, 4/2015. e-Pub 3/2015. PMCID: PMC4376596.
14. Kadia TM, Ravandi F, Cortes J, Kantarjian H. Towards Individualized Therapy in Acute Myeloid Leukemia. JAMA Oncol. Published online April 30, 2015. doi:10.1001/jamaoncol.2015.0617, 4/2015.
15. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, and Kantarjian H. Final Results of the Phase II Trial of Clofarabine and Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Cancer, 2/2015.
16. Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine. Biomed Res Int 2015:497597, 2015. e-Pub 1/2015. PMCID: PMC4310492.
17. Dinardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Piece S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian H, and Garcia-Manero G. Sequential azacytidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm phase I/II study. The Lancet Hematology, 12/2014.
18. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma. e-Pub 11/2014. PMID: 25120050.
19. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. Cancer. e-Pub 11/2014. PMID: 25410759.
20. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II Study of Methotrexate, Vincristine, Pegylated-Asparaginase, and Dexamethasone (MOpAD) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Am J Hematol. e-Pub 11/2014. PMID: 25368968.
21. Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a cd22 monoclonal antibody. Am J Hematol. e-Pub 11/2014. PMID: 25407953.
22. Kadia, T, Ravandi, F, O'Brien, S, Cortes, J, Kantarjian, H. Progress in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia, 11/2014.
23. Willis L, Rexwinkle A, Bryan J, Kadia TM. Recent Developments in Drug Therapy for Aplastic Anemia. Ann Pharmacother 48(11):1469-1478, 11/2014. e-Pub 9/2014. PMID: 25184310.
24. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 10/2014. e-Pub 5/2014. PMCID: PMC4167474.
25. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. e-Pub 10/2014. PMID: 25312977.
26. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 89(10):964-8, 10/2014. e-Pub 7/2014. PMID: 24990142.
27. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 9/2014. PMID: 25441108.
28. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 9/2014. e-Pub 7/2014. PMCID: PMC4157096.
29. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma 55(8):1925-9, 8/2014. e-Pub 2/2014. PMCID: PMC4139917.
30. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. e-Pub 7/2014. PMID: 25042398.
31. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes. Leuk Lymphoma. e-Pub 7/2014. PMID: 24844364.
32. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk 14(3):223-30, 6/2014. e-Pub 11/2013. PMCID: PMC4096861.
33. Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma 55(6):1431-4, 6/2014. e-Pub 11/2013. PMCID: PMC4105975.
34. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 55(6):1337-44, 6/2014. e-Pub 10/2013. PMCID: PMC4143910.
35. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 14(3):231-8, 6/2014. e-Pub 12/2013. PMID: 24440659.
36. Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol 89(5):509-16, 5/2014. e-Pub 2/2014. PMID: 24458781.
37. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol 5(2):29-34, 4/2014. PMCID: PMC3949300.
38. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 20(8):2226-35, 4/2014. e-Pub 2/2014. PMCID: PMC3989412.
39. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk 14(2):163-71, 4/2014. e-Pub 1/2014. PMID: 24461514.
40. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4):973-5, 4/2014. e-Pub 10/2013. PMID: 24157581.
41. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 14(2):155-162.e1, 4/2014. e-Pub 12/2013. PMCID: PMC3959284.
42. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia. Am J Hematol 88(11):961-6, 11/2013. e-Pub 9/2013. PMID: 23877926.
43. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37(11):1440-4, 11/2013. e-Pub 7/2013. PMID: 23890523.
44. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831-7, 10/2013. e-Pub 7/2013. PMCID: PMC3923606.
45. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clin Lymphoma Myeloma Leuk 13(5):592-6, 10/2013. e-Pub 6/2013. PMID: 23790798.
46. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 9/2013. e-Pub 8/2013. PMID: 23969309.
47. Jain P, Benjamini O, Pei L, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov Z. Central nervous system Richter's transformation and parvovirus B19 infection. Leuk Lymphoma 54(9):2070-2, 9/2013. e-Pub 3/2013. PMID: 23320889.
48. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S289-94, 9/2013. e-Pub 8/2013. PMID: 23969308.
49. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-62, 6/2013. e-Pub 4/2013. PMCID: PMC3674666.
50. Jain P, Sargent RL, Konoplev SN, Benjamini O, Kantarjian H, Kadia T. Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase. Am J Hematol 88(5):433-4, 5/2013. e-Pub 3/2013. PMID: 23460270.
51. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 88(5):365-9, 5/2013. e-Pub 3/2013. PMID: 23512829.
52. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia 27(4):836-42, 4/2013. e-Pub 11/2012. PMID: 23135353.
53. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 3/2013. e-Pub 1/2013. PMID: 23345254.
54. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients withadvanced myeloid malignancies. Haematologica 98(2):217-21, 2/2013. e-Pub 8/2012. PMCID: PMC3561428.
55. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 1/2013. e-Pub 10/2012. PMID: 23115106.
56. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550-9, 11/2012. e-Pub 5/2012. PMCID: PMC3416961.
57. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 9/2012. e-Pub 1/2012. PMID: 22282348.
58. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-70, 9/2012. e-Pub 1/2012. PMID: 22252728.
59. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internaltandem duplication (FLT3-ITD) at complete response and relapsein patients with acute myeloid leukemia. Haematologica 97(8):1242-5, 8/2012. e-Pub 4/2012. PMCID: PMC3409823.
60. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 8/2012. e-Pub 6/2012. PMID: 22718840.
61. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 8/2012. e-Pub 4/2012. PMID: 22534616.
62. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 118(14):3556-64, 7/2012. e-Pub 12/2011. PMID: 22139909.
63. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk 12(3):197-200, 6/2012. PMID: 22578814.
64. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs 30(3):1107-15, 6/2012. e-Pub 4/2011. PMID: 21494838.
65. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol 30(18):2204-10, 6/2012. e-Pub 5/2012. PMID: 22585696.
66. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 5/2012. e-Pub 2/2012. PMID: 22360602.
67. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. e-Pub 5/2012. PMID: 22605576.
68. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665-73, 5/2012. e-Pub 10/2011. PMID: 22020636.
69. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 3/2012. e-Pub 1/2012. PMCID: PMC3311242.
70. Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. Hypocellular acute myeloid leukemia in adults: clinical outcome analysis of 123 patients. Haematologica 97(2):235-40, 2/2012. e-Pub 11/2011. PMCID: PMC3269483.
71. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 1/2012. e-Pub 11/2011. PMID: 22072492.
72. Sharp H, Grosshans D, Kadia T, Dabaja BS. Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive acute lymphoblastic leukaemia. BMJ Case Rep 2012, 2012. e-Pub 7/2012. PMID: 22787181.
73. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 38(5):682-92, 10/2011. PMID: 21943675.
74. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 29(23):3173-8, 8/2011. e-Pub 7/2011. PMID: 21747082.
75. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol 29(18):2507-13, 6/2011. e-Pub 5/2011. PMID: 21555694.
76. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 11/2010. e-Pub 7/2010. PMID: 20668231.
77. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 6(7):976-8, 10/2010. e-Pub 10/2010. PMID: 20729640.
78. Parikh SA, Kadia T, Jabbour E. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. Clin Lymphoma Myeloma Leuk 10(4):301-2, 8/2010. PMID: 20709669.
79. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The Combination of a Histone Deacecetylase Inhibitor with the BH3-Mimetic GX15-070 has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy. Clin Cancer Res 16(15):3923-32, 8/2010. e-Pub 6/2010. PMID: 20538760.
80. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150(1):72-82, 7/2010. e-Pub 4/2010. PMID: 20456355.
81. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-7, 1/2010. e-Pub 12/2009. PMCID: PMC2815701.
82. Walker JG, Kadia T, Brown L, Juneja HS, de Groot JF. Dapsone induced methemoglobinemia in a patient with glioblastoma. J Neurooncol 94(1):149-52, 8/2009. e-Pub 2/2009. PMID: 19219404.
83. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113(9):1892-8, 2/2009. e-Pub 12/2008. PMCID: PMC2651008.
84. Kadia TM, Garcia-Manero G. Role of epigenetic therapy in myelodysplastic syndrome. Expert Rev Hematol 1(2):161-174, 12/2008. PMID: 21082921.
85. Mendez J, Kadia TM, Somayazula RK, El-Badawi KI, Cowen DS. Differential coupling of serotonin 5-HT1A and 5-HT1B receptors to activation of ERK2 and inhibition of adenylyl cyclase in transfected CHO cells. J Neurochem 73(1):162-8, 7/1999. PMID: 10386967.
Other Articles
1. Kadia, T. Chronic Lymphocytic Leukemia: New Insights Lead to More Refined, Individualized Treatment. Molecular Oncology, 1/2007.
2. Kadia, T, Jabbour E, O'Brien S. Treatment Strategies for Chronic Lymphocytic Leukemia. Oncology, 1/2006.

Abstracts

1. Jabbour, E, Sasaki, K, Daver, N, Pemmaraju, N, Jain, N, Kadia, TDiNardo, C, Tuttle, C, Borthakur, G, Konopleva, M, Faderl, S, O’Brien, S, Cortes, J, Kantarjian, H, Garcia-Manero, G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy, 12/2014.
2. Jabbour, E, Sasaki, K, Daver, N, Pemmaraju, N, DiNardo, C, Kadia, T, Miller, D, Sukholutsky, V, Huang, X, Borthakur, G, Estrov, Z, Kantarjian, H. Garcia-Manero, G,. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood, 12/2014.
3. Jabbour, E, O’Brien, S, Thomas, D, Sasaki, K, Garcia-Manero, G, Kadia, T, Jain, N, York, S, Garris, R, Cortes, J, Kantarjian, H. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 12/2014.
4. Kadia, T, Borthakur, G, Ferrajoli, A, Daver, N, Jabbour, E, Pemmaraju, N, Verstovsek, S, Burger, J, Wierda, W, Konopleva, M, DiNardo, C, Jain, N, Brandt, M, Pierce, S, Garcia-Manero, G, Cortes, J, Kantarjian, H. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood, 12/2014.
5. Jabbour, E, Kantarjian, H, Thomas, D, Sasaki, K, Ravandi, F, Cortes, J, Pemmaraju, N, Kadia, T, Garris, R, Garcia-Manero, G, Borthakur, G, Wierda, O'Brien, S. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood, 12/2014.
6. Jabbour, E, Kantarjian, H, Thomas, D, Sasaki, K, Garcia-Manero, G, Garris, R, Cortes, J, Kadia, T, Ravandi, F, Verstovsek, S, O’Brien, S. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab as Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 12/2014.
7. Jabbour, E, O'Brien, S, Sasaki, K, Huang, X, Thomas, D, Rytting, M, Garcia-Manero, G, Cortes, J, Pierce, S, Kadia, T, Kantarjian, H. Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. Blood, 12/2014.
8. Kadia, T., Thomas, X, Dmoszynska, A, Agnieszka Wierzbowska, Mark Minden, Christopher Arthur, Peter De Porre, Liang Xiu, Margaret Doyle, Jacqueline Bussolari, Hagop Kantarjian. Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts, 9/2014.
9. Kadia, T, Naval Daver, Fiona Virani, Elias Jabbour, Sherry Pierce, Naveen Pemmaraju, Alfonso Quintas-Cardama, Gautam Borthakur, Susan O'Brien, Hagop M. Kantarjian, Jorge E. Cortes. Incidence, Clinical Characteristics, and Prognostic Significance Of Chromosome 3q Abnormalities In Patients With CML Blast Phase. Blood, 12/2013.
10. Kadia, T Gautam Borthakur, Alessandra Ferrajoli, Preetesh Jain, Elias Jabbour, Srdan Verstovsek, Naveen Pemmaraju, Stefan Faderl, Farhad Ravandi, Marina Konopleva, Carla Tuttle, Mark Brandt, Xuemei Wang, Guillermo Garcia-Manero, Hagop M. Kantarjian, Jorge E. Cortes. Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML). Blood, 12/2013.
11. Jabbour, E., Hagop M. Kantarjian, Jing Ning, Guillermo Garcia-Manero, Kadia, T, Susan O'Brien, Jorge E. Cortes, Daniela Hoehn, Jeffrey Bryan, Farhad Ravandi, Verstovsek, S. Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux). Blood, 12/2013.
12. Kadia, T, Jorge E. Cortes, Deborah Thomas, Farhad Ravandi, Naveen Pemmaraju, Naval Daver, Alfonso Quintás-Cardama, Melanie Baccus, Rebecca Garris, Elias J. Jabbour, Hagop M. Kantarjian, and Gautam Borthakur. A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 11/2012.
13. Koichi Takahashi, Hagop M. Kantarjian, Hady Ghanem, Farhad Ravandi, Jorge E. Cortes, Kadia, T Susan O'Brien, Sherry A. Pierce, Nitin Jain, Guillermo Garcia-Manero, and Elias J. Jabbour. Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure. Blood, 11/2012.
14. H. Ghanem, H. Kantarjian, G. Garcia-Manero, F. Ravandi, S. Faderl, J. E. Cortes, A. Reyes, S. M. O'Brien, G. Borthakur, T. M. Kadia, J. A. Burger, M. Konopleva, E. Jabbour. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). JCO 29(15S) (#6568), 6/2011.
15. A. Al-Ameri, D. A. Thomas, F. Ravandi, S. M. O'Brien, H. Kantarjian, G. Borthakur, T. M. Kadia, M. Kelly, R. Garris, and S. Faderl. Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL). JCO (#6554), 6/2011.
16. A. Quintas-Cardama, J. E. Cortes, E. Jabbour, S. M. O'Brien, G. Garcia-Manero, J. Shan, F. Ravandi, S. Faderl, T. M. Kadia, G. Borthakur, H. Kantarjian. Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. JCO 29(15S) (#6557), 6/2011.
17. E. Jabbour, S. M. O'Brien, D. A. Thomas, F. Ravandi, S. York, M. Kwari, S. Faderl, Kadia, T, C. Wilson, R. Tarnai, A. S. Advani, G. Garcia-Manero, J. E. Cortes, H. Kantarjian. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). JCO 29(15S) (#6507), 6/2011.
18. F. Ravandi, S. Faderl, J. E. Cortes, G. Garcia-Manero, E. Jabbour, P. A. Boone, T. M. Kadia, G. Borthakur, W. G. Wierda, J. H. Chiao, H. Kantarjian. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. JCO 29(15S) (#6587), 6/2011.
19. G. Borthakur, L. Popplewell, M. H. Kirschbaum, J. M. Foran, T. M. Kadia, E. Jabbour, M. Boyiadzis, A. Verma, R. B. Walter, P. S. Wissel, L. Xu, J. W. Bauman, J. Z. Zhu, J. Mazumdar, M. Baccus, J. M. Connor, J. E. Cortes, H. Kantarjian. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. JCO 29(15) (#6506), 6/2011.
20. Kadia, T,, G. Garcia-Manero, H. Kantarjian, N. Pemmaraju, K. Stein, A. Teng, J. E. Cortes. Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. JCO 29(15S) (#6617), 6/2011.
21. A. Al-Kali, S. N. Konoplev, E. Lin, T. M. Kadia, S. Faderl, F. Ravandi Kashani, M. Ayoubi, M. Brandt, H. Kantarjian, G. Borthakur. Hypocellular acute myeloid leukemia: Better or worse prognosis. JCO 28(15) (#6561), 6/2010.
22. N. Pemmaraju, H. Kantarjian, S. Faderl, G. Garcia-Manero, T. M. Kadia, G. Borthakur, J. E. Cortes, F. Ravandi Kashani. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). JCO 28(15) (#6605), 6/2010.
23. Kim H, Jabbour E, Kadia TM, Borthakur G, Pierce S, Shan J, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Garcia-Manero G,. A Prognostic Model of Therapy - Related Myelodysplastic syndrome. Blood 114(22):1460, 11/2009.
24. Kadia TM , Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, Verstosvek S, Newsom W, Zwiebel J, Egorin M, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. Poster Presentation, American Society of Hematology Meeting, 12/2007.
25. Thompson MA, Kadia TM , Bekele BN, Wang M, Romaguera JE. Cyclin D1 polymorphisms as predictive and prognostic molecular markers in 90 mantle cell lymphoma patients treated with R-HyperCVAD. Poster Presentation, American Society of Hematology, 12/2007.
26. Kadia TM , Kantarjian H, Verstovesek S, Newman B, Garcia-Manero G, Borthakur G. Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS. Poster Presentation, American Society of Hematology Meeting, 12/2007.
27. Kadia TM , Borthakur G, Wierda W, Ravandi F, Faderl S, Newsome W, Zwiebel J, Egorin M, Garcia-Manero G. Phase I Study of the Combination of a DNA Topoisomerase Inhibitor, Idaruicin, with the Histone Daecetylase Inhibitor Vorinostat in Advanced Leukemia. Poster Presentation, American Society of Clinical Oncology Meeting, 5/2007.
28. Kadia TM, Rodriguez A, Fayad L, Mclaughlin P, Pro B. Retrospective Review of Angioimmunoblastic T-Cell Lymphoma: The MD Anderson Cancer Center Experience. American Society of Hematology Meeting, 12/2006.

Last updated: 9/28/2015